FAAH and breast cancer: Additionally, this model can be associated with other drugs; for instance, Slivicki et al. (2019) [81] demonstrated synergism and reduced neuropathic pain in the 4T1 breast cancer model by combining a fatty acid amide hydrolase inhibitor, which increases intracellular endocannabinoids, with paclitaxel.